Bernard Loev

This inventor holds 22 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Smithkline Corporation, Smith Kline & French Laboratories Limited. Active years: 1976-1978.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bernard Loev. Retrieved from https://idiyas.com/inventor/bernard-loev-1rwoqg61

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 22

% Patents Active = 100.0

Average Co-Inventor Count = 1.8

ph-index = 4

Forward Citations = 125(Granted Patents)

Company Filing History:

21 out of 344

Smithkline Corporation

patents

1 out of 362

Smith Kline & French Laboratories Limited

patents

Years Active: 1976-1978

Loading Chart...

Areas of Expertise:

Pharmaceutical Compositions

Gastric Acid Inhibitors

Heterocyclic Compounds

Antihypertensive Agents

Xanthenylamines

Quinolyl-Thioacetamides

Triazene Derivatives

Dihydropyridine Compounds

Prostaglandin Derivatives

Pyrimidinone

Thiopropanamides

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 4118567 - 3-Morpholino-2-heterocyclic-thiopropanamides (1978-10-03),

2. 4032656 - Aromatic prostaglandin derivatives (1977-06-28),

3. 4005208 - N-Heterocyclic-9-xanthenylamines (1977-01-25),

4. 4001241 - 2-Alkoxy(and 2-alkoxyalkyl)-2-quinolyl-thioacetamides (1977-01-04),

5. 3996364 - 9-Xanthylamin oalkylpyridine derivatives (1976-12-07),

6. 3980788 - Pharmaceutical compositions and methods of inhibiting gastric acid (1976-09-14),

7. 3976633 - Substituted cyano,trifluoromethylphenyl linear triazenes (1976-08-24),

8. 3975537 - Pharmaceutical compositions and methods of producing coronary (1976-08-17),

9. 3966946 - 1,4-Dihydropyridine compounds in treating hypertension (1976-06-29),

10. 3966945 - 2-Alkoxy(and 2-alkoxyalkyl)-2-heterocyclic-thioacetamides for inhibiting (1976-06-29),

11. 3962448 - 8-Alkyl and alkenyl-10-hydroxy-5H[1]benzopyranopyridine derivatives (1976-06-08),

12. 3961069 - Akenyl(or alkynyl) 9-xanthenyl ether compounds (1976-06-01),

13. 3956494 - Pharmaceutical compositions and methods of inhibiting gastric acid (1976-05-11),

14. 3956341 - 1,3,5-Tricarbo-1,4-dihydropyridines (1976-05-11),

15. 3956325 - 5-Heterocyclic-1,2,3,6-tetrahydro-4(5H) pyrimidinone (1976-05-11),

Title: The Innovative Contributions of Bernard Loev

Introduction: Bernard Loev is a prominent inventor based in Broomall, Pennsylvania, known for his significant contributions to the field of pharmaceutical chemistry, boasting an impressive portfolio of 22 patents. His work has been instrumental in the development of compounds that impact therapeutic approaches to various health conditions.

Latest Patents: Among his notable innovations, Loev has developed the "3-Morpholino-2-heterocyclic-thiopropanamides," which function as inhibitors of gastric acid secretion. These compounds provide critical advancements in managing gastrointestinal disorders. Another key patent is for "Aromatic Prostaglandin Derivatives," which exhibit valuable antiprostaglandin activity. These compounds are particularly significant for their role in inhibiting prostaglandin synthesis and helping to manage diarrhea induced by prostaglandin E2 (PGE2).

Career Highlights: Throughout his career, Bernard Loev has made substantial improvements in medicinal chemistry, primarily during his time at renowned institutions such as SmithKline Corporation and Smith Kline & French Laboratories Limited. His work has not only contributed to the pharmaceutical field but has also set the foundation for further research and development in drug therapy.

Collaborations: Loev has collaborated with notable peers, including Paul E. Bender and L. Martin Brenner, fostering a culture of innovation and shared knowledge within the scientific community. These collaborations have further cemented his reputation as a leading inventor in his field.

Conclusion: With a strong track record of patented inventions and collaborative efforts, Bernard Loev stands out as a key figure in the realm of pharmaceutical innovation. His contributions continue to influence the development of essential compounds that enhance therapeutic care, highlighting the impact that dedicated inventors can have on healthcare advancements.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]